PROSTATE CANCER: Are urologists ready to manage castration-resistant disease?

    loading  Checking for direct PDF access through Ovid


The progression of prostate cancer to castration-resistant disease usually marks the transition of patient care from urologist to medical oncologist. The demonstration that a new generation of oral agents, such as abiraterone acetate, can be administered before chemotherapy suggests the dynamics of advanced prostate cancer care are about to change.

Related Topics

    loading  Loading Related Articles